In coronary artery disease this medicament decreases IL-6 level, increases TGF-β and IL-22 [39,40], while in acute myocardial infarction it decreases IL-6, TNF-alfa, and C reactive protein (CRP) [41], which in both cases should lead to alleviation of inflammation-related complications. The gene discussed is IL22; the disease is coronary artery disorder.